Perceptions of deprescribing for patients with limited life expectancy in primary care
Primary Health Care Research & Development · 2026
DOI: 10.1017/s1463423625100686 ↗Kurz gefasst
Fachartikel in der Zeitschrift Primary Health Care Research & Development, 2026. Verfasst von Emma C M van Aken und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center of Expertise in Palliative Care, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Department of General …. Hauptthemen laut MEDLINE: Deprescriptions, Primary Health Care, Life Expectancy, Attitude of Health Personnel. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
The study aims to understand the perceptions of deprescribing in primary care for patients with a limited life expectancy.
Background
In the setting of limited life expectancy, medications may become inappropriate when the possible harms of use outweigh the benefits. Whilst the cessation of potentially inappropriate medications is associated with improved patient outcomes, incorporating this process into routine primary care is poorly enacted.
Methods
Qualitative interview study performed in primary care settings in the Netherlands, including primary care health professionals, patients with limited life expectancy, and their caregivers. Semi-structured interviews were conducted and analysed using inductive thematic analysis.
Findings
Three key themes emerged: (1) facilitating well-being, (2) preventing harm, and (3) dealing with uncertainty. A key goal of mediation use is to facilitate well-being, although the perceptions of this effect may not always match the reality due to changed clinical circumstances. The decision to continue or stop medication is influenced by the wish to prevent harm and to what extent participants find ways to deal with the uncertainties facing them. Reluctance to deprescribe medications is often related to uncertainties around ceasing medications, lack of clear clinical guidance, and the evolving situation of advanced illness. Integrating these discussions into routine primary care for patients with chronic and incurable illnesses may assist patients and healthcare professionals to address issues around medication use in a proactive manner and promote advance care planning discussions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Expertise in Palliative Care, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Department of General Practicehttps://ror.org/0575yy874, Utrecht, The Netherlands.
- Academic Hospice Demeter, De Bilt, The Netherlands.
- Leidsche Rijn Julius Healthcare Center, Parkwijk, Utrecht, The Netherlands.
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.
ORCID-Profile: Emma C M van Aken, Maike S van der Waal, Saskia C C M Teunissen, Matthew P Grant
Zitieren
APA
van Aken, E. C. M., van der Waal, M. S., Teunissen, S. C. C. M., Uyttewaal, A. G., Verboeket-Crul, C., Smits-Pelser, H., Geijteman, E. C. T., & Grant, M. P. (2026). Perceptions of deprescribing for patients with limited life expectancy in primary care. Primary Health Care Research & Development. https://doi.org/10.1017/s1463423625100686
Vancouver
van Aken ECM, van der Waal MS, Teunissen SCCM, Uyttewaal AG, Verboeket-Crul C, Smits-Pelser H, et al. Perceptions of deprescribing for patients with limited life expectancy in primary care. Primary Health Care Research & Development. 2026. doi:10.1017/s1463423625100686
BibTeX
@article{vanAken2026,
author = {van Aken, Emma C M and van der Waal, Maike S and Teunissen, Saskia C C M and Uyttewaal, Allegonda G and Verboeket-Crul, Cathelijne and Smits-Pelser, Hanneke and Geijteman, Eric C T and Grant, Matthew P},
title = {Perceptions of deprescribing for patients with limited life expectancy in primary care},
journal = {Primary Health Care Research & Development},
year = {2026},
doi = {10.1017/s1463423625100686}
}
EUVIMED